PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

22nd Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 16th April 2025 (Educational supporters)

siRNA therapeutics: What does a clinician need to know?

siRNA therapeutics: What does a clinician need to know?

Reports from the 22nd Virtual Closed Scientific Expert Meeting of the Editorial Board Marie Wikström Lindholm

read more »
Cost-effectiveness of PCSK9 inhibitors: Past, present and future

Cost-effectiveness of PCSK9 inhibitors: Past, present and future

Reports from the 22nd Virtual Closed Scientific Expert Meeting of the Editorial Board Anthony Wierzbicki

read more »
PCSK9 inhibition and post-prandial atherogenesis

PCSK9 inhibition and post-prandial atherogenesis

Reports from the 22nd Virtual Closed Scientific Expert Meeting of the Editorial Board Cédric Le May

read more »
ANGPTL3: A cholesterol target?

ANGPTL3: A cholesterol target?

Reports from the 22nd Virtual Closed Scientific Expert Meeting of the Editorial Board Rob Hegele

read more »